| 產(chǎn)品編號(hào) | bs-0247R-Bio |
| 英文名稱 | Rabbit Anti-EphB2/Biotin Conjugated antibody |
| 中文名稱 | 生物素標(biāo)記的酪氨酸蛋白激酶受體B2抗體 |
| 別 名 | Eph receptor B2; Developmentally regulated EPH related tyrosine kinase; DRT; ELK related protein tyrosine kinase; EPH tyrosine kinase 3; EphB2; Ephrin type B receptor 2; EPHT 3; ERK; ETECK; Nuk; Prkm 5; Receptor protein tyrosine kinase HEK 5, Sek 3; Tyro 5; Tyrosine protein kinase receptor CEK 5; Tyrosine protein kinase receptor EPH 3; Tyrosine protein kinase receptor QEK 5; EPHB2_HUMAN. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買 大包裝/詢價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 腫瘤 免疫學(xué) 生長(zhǎng)因子和激素 |
| 抗體來(lái)源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | Human, Mouse, (predicted: Rat, Chicken, Dog, ) |
| 產(chǎn)品應(yīng)用 | WB=1:50-200 ELISA=1:100-1000 IHC-P=1:50-200 IHC-F=1:50-200 ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 114kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human EphB2 R |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Eph receptors play important roles in axon guidance at the midline. In the auditory system, growth of axons across the midline is an important determinant of auditory function. The avian cochlear nucleus, n. magnocellularis (NM), makes bilateral projections to its target, n. laminaris (NL). Subunit: Heterotetramer upon binding of the ligand. The heterotetramer is composed of an ephrin dimer and a receptor dimer. Oligomerization is probably required to induce biological responses. Interacts (via PDZ-binding motif) with GRIP1 and PICK1 (via PDZ domain). Interacts with ARHGEF15; mediates ARHGEF15 phosphorylation, ubiquitination and degradation by the proteasome. Interacts with AQP1; involved in endolymph production in the inner ear. Subcellular Location: Cell membrane; Single-pass type I membrane protein. Cell projection, axon. Cell projection, dendrite. Tissue Specificity: Brain, heart, lung, kidney, placenta, pancreas, liver and skeletal muscle. Preferentially expressed in fetal brain. DISEASE: Defects in EPHB2 may be a cause of susceptibility to prostate cancer (PC) [MIM:176807]. It is a malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma. Note=EPHB2 mutations have been found in a prostate cancer cell line derived from a brain metastasis. Similarity: Belongs to the protein kinase superfamily. Tyr protein kinase family. Ephrin receptor subfamily. Contains 1 Eph LBD (Eph ligand-binding) domain. Contains 2 fibronectin type-III domains. Contains 1 protein kinase domain. Contains 1 SAM (sterile alpha motif) domain. Database links: Entrez Gene: 2048 Human Entrez Gene: 13844 Mouse Omim: 600997 Human SwissProt: P29323 Human SwissProt: P54763 Mouse Unigene: 523329 Human Unigene: 250981 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 生長(zhǎng)因子和激素（ Growth Factor and Hormones） EphB2受體(Ephrin type-B receptor 2)在細(xì)胞生長(zhǎng)、分化和信號(hào)轉(zhuǎn)導(dǎo)過(guò)程中具有重要作用。有報(bào)道：EphB2受體(ephrinB2受體) 在中樞神經(jīng)組織，腫瘤組織有較強(qiáng)的表達(dá)。促進(jìn)腫瘤細(xì)胞浸潤(rùn)和新生血管形成. |
